Table 1 Patient characteristics
From: Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery
All patients (n = 23) | Transient PSA elevation (n = 11) | PSA decline (n = 12) | p-value | |
|---|---|---|---|---|
Follow-up (months) | 0.14 | |||
Median | 63 | 44 | 57 | |
Range | 30–112 | 30–112 | 53–95 | |
Age (years) | 0.48 | |||
Median | 67 | 67 | 67 | |
Range | 54–76 | 57–76 | 54–73 | |
T-Stage | 0.14 | |||
T2a/T2c | 3/ 9 | 1/ 5 | 2/ 6 | |
T3a/T3b | 7/ 4 | 5/ 2 | 2/ 2 | |
Initial PSA (ng/ml) | 0.16 | |||
Median | 11.37 | 13.83 | 8.72 | |
Range | 3.22–40.6 | 3.22–40.6 | 4.76–17.96 | |
Gleason score | 0.79 | |||
7 | 18 | 8 | 10 | |
8/ 9 | 3/ 2 | 3/ 1 | 0/ 1 | |
D’Amico risk group classification | ||||
Low risk | 0 | 0 | 0 | |
Intermediate risk | 2 | 0 | 2 | |
High risk | 21 | 11 | 10 | |
Pathological diagnosis | ||||
ly1 | 11 | 7 | 4 | 0.16 |
pn1 | 20 | 9 | 11 | 0.51 |
sv1 | 4 | 2 | 2 | 0.93 |
v1 | 3 | 3 | 0 | 0.08 |
EPE1 | 12 | 6 | 6 | 0.84 |
RM1 | 17 | 9 | 8 | 0.43 |